B, consensus $8.5B. CEO Steve Cutler commented, “ICON (ICLR) continues to navigate dynamic clinical development ...
Analyst Michael Cherny from Leerink Partners reiterated a Buy rating on Icon (ICLR – Research Report) and decreased the price target to $245.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback